Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Completed 3Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 123Carcinoma, Hepatocellular 72Breast Neoplasms 48Neoplasms 47Small Cell Lung Carcinoma 45Lung Neoplasms 41Triple Negative Breast Neoplasms 40Colorectal Neoplasms 38Melanoma 35Urinary Bladder Neoplasms 33Neoplasm Metastasis 31Carcinoma, Transitional Cell 31Carcinoma, Renal Cell 28Ovarian Neoplasms 20Uterine Cervical Neoplasms 19Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 17Head and Neck Neoplasms 15Liver Neoplasms 13Prostatic Neoplasms 12Glioblastoma 12Solid Tumors 11Recurrence 11Sarcoma 10Esophageal Neoplasms 10Pancreatic Neoplasms 9Lymphoma 9Endometrial Neoplasms 9Mesothelioma, Malignant 8Kidney Neoplasms 8

Interventions

Gemcitabine 91Cisplatin 69Oxaliplatin 37Capecitabine 37durvalumab 29Fluorouracil 26pembrolizumab 24Leucovorin 22S 1 (combination) 18Nivolumab 13Irinotecan 13lenvatinib 12Bevacizumab 11tremelimumab 10apatinib 8Trastuzumab 7Injections 7Albumin-Bound Paclitaxel 7130-nm albumin-bound paclitaxel 7Paclitaxel 6Immune Checkpoint Inhibitors 6Docetaxel 6titanium silicide 5surufatinib 5envafolimab 5camrelizumab 5atezolizumab 5Folfox protocol 5Drug Therapy 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Biliary Tract Neoplasms × atezolizumab × Clear all
NCT05733598 2026-04-02

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Replimune, Inc.

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT05052099 2025-09-29

COMBATBIL

University Hospital, Essen

Phase 1/2 Completed
20 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT04677504 2024-07-03

A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

Hoffmann-La Roche

Phase 2 Completed
162 enrolled 18 charts
Gastrointestinal

Biliary Tract Neoplasms

NCT03818997 2020-02-05

DYNAMIC

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn
Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡